Axsome Therapeutics competitors

Dr. Walker is President and Chief Executive Officer at Aclaris Therapeutics. He is also a co-founding partner of NeXeption, LLC, a biopharmaceutical management company. He is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the biopharmaceutical industry. Prior to founding Aclaris, he was co-founder, President and CEO of Vicept Therapeutics (acquired by Allergan). Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories); Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb. He began his pharmaceutical industry career at Johnson and Johnson. Dr. Walker co-founded and is Vice Chairman of Alexar Therapeutics, Inc. and serves on the Board of Directors of Sebacia, Inc. He also co-founded and serves on the Board of Directors of the Dermatology Summit, an Advancing Innovation in Dermatology Conference. He previously served on the Board of Directors for Octagon and the Advisory Board of Flexible Medical Systems. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania.

Dr. Travis Mickle founded KemPharm, Inc. in late 2006. Prior to KemPharm, from January 2003 to October 2005, Dr. Mickle was Director of Drug Discovery and Chemical Development at New River Pharmaceuticals where he also served in a variety of other senior research roles since joining the firm in 2001. During his tenure at New River, Dr. Mickle was responsible for creating a strong preclinical and clinical pipeline of drugs in the areas of ADHD, pain and thyroid dysfunction. His contributions included, as principal inventor, the discovery and development of lisdexamfetamine dimesylate, the highly successful therapy for the treatment of ADHD known as Vyvanse®. In addition, Dr. Mickle was an active participant in FDA and DEA meetings representing the company’s discovery/chemistry group and was also called in as a critical scientific resource during New River’s financings and strategic partnering discussions. Before his departure, Dr. Mickle played an integral part in New River’s development into a successful publicly-traded company which was subsequently acquired for $2.6 billion by its marketing partner, Shire PLC. Dr. Mickle is also the author of over 150 U.S. and international patents and patent applications, as well as several research papers. Dr. Mickle holds a Ph.D. in Bio-Organic Chemistry from the University of Iowa.

Remy is the CEO of Minerva Neurosciences (Nasdaq: NERV) and was formerly an advisor to Index Ventures, Chief Medical Officer of the Index Life VI biotech fund raised by Index Ventures in 2012, and a member of the Scientific Advisory Board of the fund.

Gregory A. Demopulos, M.D. is one of our founders and has served as our President, Chief Executive Officer and Chairman of the Board of Directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training at Duke University. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

Phillip Frost is a Board Member at Ym Biosciences Inc., General Partner at Peregrine Ventures Management Ltd, and Board Member at Protalix Ltd and is based in Miami Beach, Florida. He has worked as Governor at American Stock Exchange; Board Member at COCRYSTAL PHARMA, INC.; and Chairman:Dermatology at Mount Sinai. Phillip works or has worked as TRUSTEE at Frost Nevada Investments Trust, BOARD MEMBER at Shanghai Institute for Advanced Immunochemical Studies, and BOARD MEMBER at Smithsonian Institution. He studied at University of Pennsylvania until 1957, Yeshiva University, and Albert Einstein College of Medicine until 1961.

Mr. Singh joined our Board of Directors in 2000 and our management team in 2003 following our acquisition of Artemis Neuroscience, of which he was President. Mr. Singh has nearly 20 years of experience working with biopharmaceutical companies. He currently serves as Managing Principal of Cato BioVentures, a life science venture capital firm affiliated with Cato Research, a leading contract research organization. Mr. Singh also serves in management and director roles for Echo Therapeutics and Hemodynamic Therapeutics, each a Cato BioVentures portfolio company. Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN) and as a Corporate Finance Associate of Morrison & Foerster, an international law firm. Mr. Singh is a member of the State Bar of California.

Sergio Traversa is a Chief Executive Officer at Relmada Therapeutics.

J have worked as Chairman/Pres/CEO/Secy/Co-Founder at Genprex Inc. They work or have worked as MEMBER at STATE BAR OF TEXAS. J attended TAMU and University of Texas School of Law.